Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|October 22, 2010
- The Column-10-22-2010
- Volume 6
- Issue 19
Summer Reflections (Part 2)
Incognito turns his attention in the second part of this series to looking at ways of decreasing analysis time in capillary GC.
Advertisement
Still pondering the advances in chromatographic techiniques, Incognito turns his attention in the second part of this series to looking at ways of speeding up GC analysis by examining the heating/cooling dilemma.
Articles in this issue
about 16 years ago
Changing namesabout 16 years ago
Power plantabout 16 years ago
Multiple reaction monitoring atlasabout 16 years ago
Purifying proteinsabout 16 years ago
Q&A: Sourcing It Outabout 16 years ago
Market Profile: UHPLCAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5